Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$12.82
-2.4%		$16.05
$8.72
▼
$27.41
$476.19M1.27327,177 shs397,809 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.25
+0.9%		$0.26
$0.21
▼
$0.69
$269.07M0.34790,630 shs297,048 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-2.44%+8.28%-9.65%-21.35%+0.71%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
+0.93%+1.46%+0.36%-35.54%-57.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$12.82
-2.4%		$16.05
$8.72
▼
$27.41
$476.19M1.27327,177 shs397,809 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.25
+0.9%		$0.26
$0.21
▼
$0.69
$269.07M0.34790,630 shs297,048 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-2.44%+8.28%-9.65%-21.35%+0.71%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
+0.93%+1.46%+0.36%-35.54%-57.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.00
Buy$33.00157.41% Upside
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CBIO and ELTP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/19/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$36.00
10/19/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$36.00
10/6/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral ➝ Buy$36.00
9/14/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$27.00
8/27/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$27.00
8/24/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
8/7/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$11.88M40.07N/AN/A$14.32 per share0.90
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$148.87M1.81$0.03 per share9.27$0.09 per share2.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$153.94M-$6.72N/AN/AN/AN/A-101.50%-86.86%11/5/2026 (Estimated)
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$44.87M$0.046.25N/AN/A40.19%44.58%29.54%11/12/2026 (Estimated)

Latest CBIO and ELTP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026N/A
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.6739N/AN/AN/A$0.36 millionN/A
8/13/2026Q1 2027
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.01N/AN/A
7/30/2026Q2 2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.7357-$0.74-$0.0043-$0.74$0.36 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
9.66
9.66
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.03
3.76
2.97

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
24.84%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
4437.14 million27.92 millionOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
651.08 billion921.81 millionNot Optionable

Recent News About These Companies

Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?
October 21 at 3:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31141814
Elite Pharmaceuticals (OTCMKTS:ELTP) Share Price Breaks Below 200 Day Moving Average - Should You Sell?
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31113641
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
October 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3002015/elite-pharmaceuticals-vs-aytu-which-cns-stock-is-the-better-buy?cid=cs-stocknewsapi-ft-microcap_article|investment_ideas-3002015
ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility
September 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2987951/eltp-downgraded-to-neutral-on-pricing-pressure-limited-visibility?cid=cs-stocknewsapi-ft-microcap_article-2987951
Elite Pharmaceuticals Earnings Call Highlights Steady Growth
August 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ELTP/pressreleases/4154202/elite-pharmaceuticals-earnings-call-highlights-steady-growth/
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
August 25, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2979833/eltp-vs-derm-which-specialty-pharmaceutical-stock-is-the-better-buy?cid=cs-stocknewsapi-ft-microcap_article|investment_ideas-2979833
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
August 19, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2977178/elite-pharmaceuticals-stock-plunges-post-q1-earnings-revenues-fall-y-y?cid=cs-stocknewsapi-ft-microcap_article|earnings-2977178
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936884-elite-pharmaceuticals-inc-eltp-q1-2027-earnings-call-transcript
Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call ...
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69307894-elite-pharmaceuticals-inc-elite-pharmaceuticals-inc-reports-financial-results-for-the-first-quarter-of-fiscal-year-2027-ended-june-30-2026-and-p-296.htm
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
August 13, 2026  |  newsfilecorp.comN
Elite Pharmaceuticals to Announce Q1 2027 Results
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ELTP/pressreleases/3791642/elite-pharmaceuticals-to-announce-q1-2027-results/
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
August 10, 2026  |  newsfilecorp.comN
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
August 4, 2026  |  newsfilecorp.comN
Possible Generic Drug Tariffs and 2 Microcaps
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965296/possible-generic-drug-tariffs-and-2-microcaps?cid=cs-stocknewsapi-ft-microcap_article-2965296
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
July 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2954132/eltp-vs-cpix-which-pharma-stock-is-the-better-buy-right-now?cid=cs-stocknewsapi-ft-microcap_article|investment_ideas-2954132
Elite Pharmaceuticals Stock Slips Despite Record Fiscal 2026 Earnings
July 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2947858/elite-pharmaceuticals-stock-slips-despite-record-fiscal-2026-earnings?cid=cs-stocknewsapi-ft-microcap_article|earnings-2947858
Elite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and ...
July 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/elite-pharmaceuticals-inc-eltp-q4-010036969.html
Elite Pharmaceuticals, Inc. (ELTP) Q4 2026 Earnings Call Transcript
June 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918919-elite-pharmaceuticals-inc-eltp-q4-2026-earnings-call-transcript
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
June 29, 2026  |  newsfilecorp.comN
ELITE PHARMS INC by Elite Pharmaceuticals, Inc. Earnings Estimates, EPS & Revenue | OTC:ELTP
June 28, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ELTP/earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$12.82 -0.32 (-2.44%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$12.83 +0.01 (+0.08%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.25 +0.00 (+0.93%)
As of 10/23/2026 03:58 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas